NeoGenomics (NASDAQ:NEO - Get Free Report) announced its quarterly earnings results on Tuesday. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06), Zacks reports. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. The company's revenue was up 7.6% compared to the same quarter last year. NeoGenomics updated its FY 2025 guidance to EPS.
NeoGenomics Stock Down 29.3 %
Shares of NeoGenomics stock traded down $2.93 on Tuesday, hitting $7.05. The company had a trading volume of 3,016,691 shares, compared to its average volume of 979,268. The stock has a 50 day moving average of $9.74 and a 200-day moving average of $13.45. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics has a 1 year low of $7.02 and a 1 year high of $19.12. The stock has a market capitalization of $906.39 million, a price-to-earnings ratio of -11.43 and a beta of 1.41.
Analysts Set New Price Targets
NEO has been the subject of a number of recent analyst reports. Needham & Company LLC dropped their target price on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a research note on Monday, January 13th. Bank of America cut their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 19th. The Goldman Sachs Group decreased their price objective on shares of NeoGenomics from $17.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, Piper Sandler dropped their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $19.30.
View Our Latest Analysis on NEO
About NeoGenomics
(
Get Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
